INTRODUCTION {#s1}
============

Alzheimer\'s disease acts as the most common one in all kinds of dementia, especially in the elderly populations, and the prevalence of AD is always increasing in recent years \[[@R1]\]. AD was featured as classic cognitive deficits (memory impairment), change of behaviors, insomnia, and dysfunction of body autonomy. The treatment at an early stage is very important. Most of recent treatment options for AD patients mainly concentrated on preventing the decline of cognition by way of medications \[[@R2], [@R3]\]. In view of less pharmacological options, other nonpharmacological therapeutic strategies were emerging in recent years \[[@R4], [@R5]\], of which the transcranial magnetic stimulation has been recommended as an useful and effective noninvasive option.

Repetitive transcranial magnetic stimulation has been reported as a non-invasive tool to regulate and balance the activity of neural cells. It should be noted that rTMS has some advantages in the safety and non-invasive property \[[@R6], [@R7]\], and rTMS can combine some different medications and other stimuli \[[@R8]--[@R10]\]. To date, many clinical and basic studies have indicated that rTMS can effectively improve the clinical manifestation of AD, Parkinson\'s disease (PD) and schizophrenia. Mechanically, rTMS is able to mediate the neural plasticity and reduce an imbalance between excitation and inhibition signals \[[@R11]--[@R13]\]. As reported, TMS stimulated cortical neurons by generation of magnetic fields to activate the synaptic activities of neuronal circuits in the central neural system \[[@R14]\]. High-frequency TMS has been used for various psychiatric and neurological diseases, including depression, schizophrenia, and Parkinson\'s disease \[[@R15]\]. However, the role of rTMS in improving cognitive functions of AD patients was less reported.

This study aims to investigate the clinical efficacy of rTMS in ameliorating cognitive levels of patients with AD by the prospective, randomized, double-blind and placebo-controlled trial, and then we analyzed the clinical efficacy of rTMS in mild and moderate AD patients. Our findings suggested that repetitive transcranial magnetic stimulation improves cognitive level, memory and language of AD patients, especially in the mild stage of AD patients. Thus, rTMS can be recommended as a promising adjuvant therapy combined with cholinesterase inhibitors at the mild stage of AD patients.

RESULTS {#s2}
=======

Baseline level of participants {#s2_1}
------------------------------

To figure out the baseline of participants, we firstly analyzed the demographic differences, including age, male-to-female ratio and donepezil level. In the present study, 17 AD patients were enrolled and randomly attributed to the rTMS treatment group and the other 13 participants were also randomly attributed into the non-rTMS sham group. As shown in Table [1](#T1){ref-type="table"}, we found that there were no significant differences between the treatment and control groups in age (*p* = 0.313), male-to-female ratio (*p* = 1.000), education level (*p* = 0.921), and donepezil level (*p* = 0.751), indicating that both groups can be used as this scientific trial. During this trial, three participants including two patients in rTMS treatment group and one in the sham group had the adverse effect, and they had the mild headache and fatigue after the first treatment. But these three participants were willing to finish this trial. Subsequently they did not have these adverse effects. Mostly, we did find no significant differences between these two groups in related baseline levels including ADAS-cog (*p* = 0.474), MMSE (*p* = 0.536), MoCA (*p* = 0.810) and WHO-UCLA AVLT scores (0.591) (Table [1](#T1){ref-type="table"}).

###### Baseline characteristics of all participants

  Indications               Mean (*n* = 30)   rTMS group (*n* = 17)   Sham group (*n* = 13)   *p* -value
  ------------------------- ----------------- ----------------------- ----------------------- ------------
  Age (years)               70.8±5.6          69.3±5.8                71.4±5.2                0.313
  Females (%)               56.7              58.8                    54.8                    1.000
  Education level (years)   4.9±2.3           4.8±1.9                 4.9±3.5                 0.921
  Donepezil (mg)            8.2±2.2           8.0±2.5                 8.3±2.6                 0.751
  ADAS-cog                  23.6±6.9          22.6±5.9                24.2±6.1                0.474
  MMSE                      22.5±2.7          22.2±2.8                22.8±2.3                0.536
  MoCA                      17.9±5.8          17.5±6.2                18.1±7.3                0.810
  WHO-UCLA AVLT             33.1±8.7          32.5±7.9                34.1±8.1                0.591

ADAS-cog score {#s2_2}
--------------

Using ADAS-cog scale, we compared ADAS-cog score in the rTMS treatment group with that in the sham group based on the baselines. Firstly, there was no significant differences in the group-by-time interaction (*p* = 0.332), with which we can figure out the role of the ADAS-cog score in the treatment group and the sham group very well. Next we found that all 17 AD patients in the rTMS group showed an significant increase by 4.1 ADAS-cog scores after the first 6 weeks of rTMS treatment (*p* = 0.042), and a more significant increase by 5.8 ADAS-cog scores after 12 weeks of rTMS treatment (*p* = 0.013). Whereas, the ADAS-cog scores in the sham group exhibited no significant increase by 1.3 and 3.0 points immediately and 6 weeks after non-rTMS treatment (*p* = 0.668, *p* = 0.315, respectively) (Figure [1a](#F1){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Besides, the ADAS-cog score in the mild treatment group significantly improved much more compared with that in the mild sham group (Figure [1b](#F1){ref-type="fig"}). However, the ADAS-cog score in the moderate treatment group insignificantly improved compared with that in the moderate sham group (Figure [1c](#F1){ref-type="fig"}), indicating that rTMS has more advantages in treating the mild AD patients.

![Differences in ADAS-cog score at each time point (baseline, immediately after, 6 weeks after the treatment)\
There was no significant time-by-group interaction in spite of significant improvements in the treatment group. The red line represents the sham group and the green line represents the treatment group. \**p* \< 0.05, v.s. baseline.](oncotarget-08-33864-g001){#F1}

###### Neuropsychological assessment scores at all participants and in the mild and moderate group

  Neuropsychological assessments   Group (*n*)      Mean Scores (SD)   *p* value                                     
  -------------------------------- ---------------- ------------------ ------------ ------------ --------- --------- -------
  ADAS-cog                         Treatment (17)   22.6 (5.9)         18.5 (5.4)   16.8 (6.9)   0.042\*   0.013\*   0.332
  Sham (13)                        24.2 (6.1)       22.9 (8.9)         21.2 (8.6)   0.668        0.315               
  Mild-treatment (12)              20.6 (5.2)       16.4 (4.4)         14.2 (6.8)   0.044\*      0.017\*   0.263     
  Mild-sham (8)                    21.7 (4.6)       20.3 (5.6)         19.4 (6.8)   0.593        0.441               
  Moderate-treatment (5)           23.8 (6.6)       20.3 (6.5)         18.9 (6.7)   0.423        0.278     0.878     
  Moderate-sham (5)                27.5 (5.9)       24.2 (8.6)         23.5 (8.5)   0.499        0.413               
  MMSE                             Treatment (17)   22.2 (2.8)         23.9 (2.5)   25.5 (4.6)   0.071     0.017\*   0.557
  Sham (13)                        22.8 (2.3)       23.1 (3.3)         24.2 (4.1)   0.790        0.294               
  Mild-treatment (12)              25.6 (2.1)       27.1 (4.1)         29.7 (4.5)   0.147        0.042\*   0.639     
  Mild-sham (8)                    25.8 (2.3)       26.2 (3.5)         28.1 (3.5)   0.791        0.395               
  Moderate-treatment (5)           19.2 (2.5)       20.4 (3.3)         21.7 (4.3)   0.535        0.294     0.812     
  Moderate-sham (5)                19.5 (1.9)       20.4 (2.5)         21.5 (2.1)   0.539        0.153               
  MoCA                             Treatment (17)   17.5 (6.2)         19.8 (6.5)   21.5 (5.9)   0.299     0.063     0.552
  Sham (13)                        18.1 (7.3)       19.3 (6.7)         20.1 (6.6)   0.666        0.471               
  Mild-treatment (12)              18.6 (5.1)       21.1 (4.3)         23.1 (5.3)   0.208        0.046\*   0.799     
  Mild-sham (8)                    19.7 (7.5)       20.9 (7.1)         21.4 (7.8)   0.747        0.664               
  Moderate-treatment (5)           16.6 (6.2)       17.9 (5.8)         19.2 (5.5)   0.741        0.503     0.517     
  Moderate-sham (5)                17.5 (6.8)       18.4 (5.9)         19.5 (6.6)   0.829        0.650               
  WHO-UCLA AVLT                    Treatment (17)   32.5 (7.9)         35.8 (7.8)   38.7 (8.9)   0.229     0.039\*   0.667
  Sham (13)                        34.1 (8.1)       35.8 (7.4)         37.8 (8.7)   0.582        0.273               
  Mild-treatment (12)              35.6 (5.6)       37.9 (6.5)         41.8 (6.6)   0.363        0.021\*   0.524     
  Mild-sham (8)                    35.8 (6.7)       36.6 (6.7)         38.7 (4.5)   0.815        0.327               
  Moderate-treatment (5)           30.5 (7.6)       33.5 (2.3)         35.6 (6.3)   0.423        0.281     0.550     
  Moderate-sham (5)                30.6 (6.7)       33.9 (5.4)         36.5 (4.9)   0.416        0.151               

Repetitive measures ANOVA was adjusted with age, gender, education level, and then Bonferroni comparison was used for post-hoc analysis.

\**p* value\<0.05. NA: not applicable.

MMSE score {#s2_3}
----------

In the treatment group, the mean MMSE score ranged from 22.2 (baseline) to 23.9 (immediately after the treatment) and 25.5 (6 weeks after the end of the treatment), meanwhile, in the sham group, the mean MMSE score ranged from 22.8 (baseline) to 23.1 (immediately after the treatment) and 24.2 (6 weeks after the end of the treatment). According to statistics, there was a significant increase at 6 weeks after the end of the treatment (*p* = 0.017) instead of immediately after the treatment (*p* = 0.071). However, the MMSE score showed no significant change in the sham group (*p* = 0.790, *p* = 0.294, respectively; Figure [2a](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). In addition, the MMSE score in the mild treatment group was significantly improved as compared with that in the mild sham group (Figure [2b](#F2){ref-type="fig"}). However, the MMSE score in the moderate treatment group was insignificantly improved compared with that in the moderate sham group (Figure [1c](#F1){ref-type="fig"}), indicating that rTMS has more advantages in treating the mild AD patients.

![Differences in MMSE score at each time point (baseline, immediately after, 6 weeks after the treatment)\
There was no significant time-by-group interaction in spite of significant improvements in the treatment group. The red line represents the treatment group and the green line represents the sham group. \**p* \< 0.05, v.s. baseline.](oncotarget-08-33864-g002){#F2}

MoCA score {#s2_4}
----------

With the help of MoCA scale, we compared MoCA score in the rTMS treatment group with that in the sham group. Firstly, our data identified that the MoCA score in the treatment group and sham group showed no significant improvement at each time point. However, we found a significant increase in the mild group at 6 weeks after the end of the treatment compared with the baseline (*p* = 0.046) (Figure [3](#F3){ref-type="fig"}, Table [2](#T2){ref-type="table"}). However, the MoCA score in the moderate treatment group was insignificantly improved compared with that in the moderate sham group (Figure [3](#F3){ref-type="fig"}, Table [2](#T2){ref-type="table"}), indicating that rTMS has more advantages in treating the mild AD patients.

![Differences in MoCA score at each time point (baseline, immediately after, 6 weeks after the treatment)\
There was no significant time-by-group interaction in spite of significant improvements in the treatment group. The red line represents the treatment group and the green line represents the sham group. \**p* \< 0.05, v.s. baseline.](oncotarget-08-33864-g003){#F3}

WHO-UCLA AVLT score {#s2_5}
-------------------

Based on precise data of cognitive scores, more cognitive assessment tests were completed in the present study, and we used the WHO-UCLA AVLT score to further assess cognitive level of AD patients. Compared with the baselines, the general level of AVLT in the treatment group has much more improvement by 6.2 points at 6 weeks after the end of the treatment (*p* = 0.039; Table [2](#T2){ref-type="table"}). In addition, scores of WHO-UCLA AVLT in the treatment group were significantly higher compared with the baseline level at 6 weeks after the end of the treatment (*p* = 0.021; Table [2](#T2){ref-type="table"}); however, scores of WHO-UCLA AVLT in the sham group were no significantly changed compared with the baseline level at 6 weeks after the end of the treatment (*p* = 0.815, *p* = 0.327, respectively; Table [2](#T2){ref-type="table"}). Likewise, the AVLT score in the moderate treatment group was also insignificantly improved compared with that in the moderate sham group (Figure [4](#F4){ref-type="fig"}), indicating that rTMS has more advantages in treating the mild AD patients.

![Differences in WHO-UCLA AVLT score at each time point (baseline, immediately after, 6 weeks after the treatment)\
There was no significant time-by-group interaction in spite of significant improvements in the treatment group. The red line represents the treatment group and the green line represents the sham group. \**p* \< 0.05, v.s. baseline.](oncotarget-08-33864-g004){#F4}

More findings {#s2_6}
-------------

In this work, we further assessed cognitive domains, and observed that there was an improvement in the memory and language aspect of cognitive domains when AD patients underwent the rTMS treatment. It should be noted that these findings became more significant and effective in the mild AD patients (Table [3](#T3){ref-type="table"}). At the same time, there was no statistically significant improvement in the cognitive level in the moderate AD patients (Table [3](#T3){ref-type="table"}), indicating that rTMS may have no effect on moderate AD patients.

###### Changes of cognitive domains in the rTMS treatment group

  group                cognitive domains   changes of scores, mean (SD)   *p* value                         
  -------------------- ------------------- ------------------------------ ------------- --------- --------- -------
  treatment            memory              2.04 (2.25)                    2.62 (3.66)   0.002\*   0.009\*   0.575
  language             1.17 (1.36)         1.39 (1.67)                    0.003\*       0.003\*   0.676     
  executive function   0.86 (1.89)         0.49 (1.67)                    0.079         0.244     0.549     
  mild treatment       memory              2.56 (2.33)                    2.88 (2.87)   0.003\*   0.005\*   0.767
  language             1.36 (1.56)         1.54 (1.67)                    0.012\*       0.009\*   0.788     
  executive function   0.92 (1.12)         0.92 (1.50)                    0.016\*       0.058     1.000     
  moderate treatment   memory              1.56 (2.32)                    2.41 (3.12)   0.207     0.159     0.638
  language             0.98 (0.89)         1.15 (1.56)                    0.070         0.175     0.838     
  executive function   0.74 (0.99)         0.00 (1.11)                    0.170         1.000     0.298     

Repetitive measures analysis of covariance includes age, gender and education level as covariates; Bonferroni correction is used for multiple comparisons.

\**p* value\<0.05.

Δ: differences from baseline to at each point, \[B\]: baseline, \[[@R6]\]: immediately after the end of treatment, \[[@R12]\]: 6 weeks after the end of treatment.

DISCUSSION {#s3}
==========

Recently, repetitive transcranial magnetic stimulation has been successfully applied in diverse neuropsychiatric disorders and diseases, particularly in AD, PD and some depression symptoms \[[@R13], [@R15], [@R16]\]. High-frequency rTMS (more than 5 Hz) has been reported to deliver its signal into left dorsolateral prefrontal cortex \[[@R17], [@R18]\]. However, low-frequency rTMS (less than 1 Hz) is able to control the activity of the right dorsolateral prefrontal cortex \[[@R19], [@R20]\]. To date, the clinical role of rTMS in treatment of AD patients with cognitive deficits is still not elucidated and some results are conflicting. In the present study, we enrolled 30 AD patients and conducted the rTMS and non-rTMS therapy. We identified that a significant increase in the cognition level could be found when AD patients underwent rTMS treatment in this trial. Additionally, the neuropsychological assessments including ADAS-cog, MMSE, MoCA and WHO-UCLA AVLT showed a significant improvement in mild AD patients with the treatment of rTMS. These findings indicatied that rTMS has more advantages in treating the mild AD patients.

Till now, the physiological mechanisms underlying the treatment efficacy of rTMS have been not wholly elucidated. Some reports suggested that magnetic field of rTMS has the capacity of directly modulating specific cortical regions as well as neural networks \[[@R21]\]. In addition, because the memory and learning activity can be regulated by synaptic neuronal activities, and synaptic strength can be altered by co-activation of input neurons, rTMS may promote the neural coactivation to change synaptic strength to further facilitate memory and learning activity \[[@R21]\]. In general, high-frequency rTMS can be located into various cortical areas, which was consistent with related cognitive function in this work. Thus, rTMS might enhance the possibility of cortical plasticity, and then transduct magnetic signals to the associated cortical regions. Most reports identified that there were no significant discrepancies in cognitive change between rTMS and sham non-rTMS.

However, other studies also found that rTMS has the beneficial effects on different cognitive level, including memory, language, and executive function. Maria et al identified that rTMS has an important role in improving language and auditory sentence comprehension \[[@R22]--[@R24]\], and then another report also showed that rTMS can facilitate verbal and nonverbal agility, and attenuate some cognitive indicators in AD patients \[[@R25]\]. In accordance with these results, our findings showed that the language and memory domains were also obviously improved in AD patients with rTMS, especially in the mild treatment group.

The present study had several limitations: (1) the small sample size (a total of 30 patients) was applied in this study, which limited its statistical power and resulted in lack of actual effects. (2) The effectiveness of double-blinding and random sequence was not well evaluated, leading to bad impact on the validity of clinical trial and statistics. (3) Despite that the average donepezil level did not show any significant differences between the treatment and the sham groups, the dosage of donepezil was not well defined at the beginning of the trial, and the blood detection of donepezil was not conducted in this trial. Thus, the other role of donepezil may influence the actual effect of rTMS on AD patients; (4) the frequency of rTMS might not be enough to obtain effective clinical data, which may need long-time or higher frequency treatment.

In conclusion, this study suggested that repetitive transcranial magnetic stimulation improves cognitive level, memory and language of AD patients, especially in the mild stage of AD patients. Thus, rTMS can be recommended as a promising adjuvant therapy combined with cholinesterase inhibitors at the mild stage of AD patients. Further trials with larger sample size are available to determine the optimal treatment indicators, involving rTMS orientation and periods.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

The ethical committee of Qilu Hospital of Shandong University had approved all procedures and all subjects gave their written informed consent prior to participation. The study was performed in agreement with the Declaration of Helsinki.

Study population {#s4_2}
----------------

### Inclusion criteria {#s4_2_1}

Thirty patients (17 patients receiving rTMS treatment and 13 receiving sham treatment) diagnosed with AD based on the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition were recruited for this study. Their MMSE score was 18-26 and their global Clinical Dementia Rating scale score was 1 or 2. All of the participants in this study were required to be accompanied by a caregiver or a family member who spent more than 72 hours per week with the patient to provide daily information about them. All patients could read and write Chinese proficiently, and brain MRI was performed to exclude any organic brain lesions that might have affected cognitive function. The patients were required to maintain their drugs without changes from at least 2 months before the start of the study and throughout its duration.

### Exclusion criteria {#s4_2_2}

Patients with a history of alcohol abuse or who had taken psychoactive medications within the past month were excluded. Patients who were not capable of touching a computer screen, who were unable to cooperate with the technician because of vision or hearing difficulty, or who had contraindications for rTMS were also excluded, as were patients who were not available for general TMS treatment.

Study design {#s4_3}
------------

This was a prospective, randomized, double-blind, placebocontrolled study that was conducted from February 2014 to February 2015. The patients were randomly assigned to the treatment or sham-treated group. The patients in the treatment group received daily treatment sessions for 6 weeks (1 session/day and 5 days/week for total of 30 sessions), while the sham-treated group received regular sham management without stimulation. The treatment areas included parietal P3/P4 and posterior temporal T5/T6 according to electroephalogram 10-20 system. Neuropsychological assessments were performed before the treatment and immediately after and 6 weeks after the end of rTMS.

Treatment procedure {#s4_4}
-------------------

The patients in the treatment group received daily treatment sessions for 6 weeks (1 session/day and 5 days/week for total of 30 sessions in 6 weeks). Each session lasted 1 hour, including preparation, and three brain areas were targeted and stimulated separately. 10 min of rTMS (10 s of 20 Hz/train, 20s intermediate/train) followed by two to four cognitive tasks were administered over the course of 20-40 s for each brain area. For patients in the sham group, the same coil was positioned for stimulating the same selected brain areas but without applying any magnetic stimulation, and the patients heard the same sounds that had been recorded for when stimulation was applied to the other patients. All AD patients were administrated with the same basic treatment such as cholinesterase inhibitors and donepezil.

Clinical assessments and analyzed variables {#s4_5}
-------------------------------------------

All measurements of clinical assessments were repeated three times: at baseline and then immediately and 6 weeks after the end of TMS treatment. The initial evaluation was performed 2 weeks before starting TMS treatment. The second evaluation was performed at the time that the 6-weeks stimulation period was completed, and the final evaluation was performed 6 weeks after the end of TMS treatment. Patients were also divided into two groups according to the severity of AD using the cutoff MMSE score of 21: mild group, 21-26; and moderate group, \< 20. All cognitive assessments were performed by a trained neuropsychologist who was blinded to the treatment status of the participants (i.e., treated or sham-treated) throughout the study.

Neuropsychological tests {#s4_6}
------------------------

Semi-structured interviews were used to collect all subjects' demographic data, vascular risk factors (hypertension, diabetes, high cholesterol, heart disease, smoking, etc.) as well as their current and past medical histories. All subjects were also given a detailed neurological examination and neuropsychological assessment. The main test questionnaire included:

The Chinese version of Alzheimer\'s Disease Assessment Scale-cognitive subscale (ADAS-cog). It was measured at each time point. The ADAS-cog, a widely used cognitive assessment instrument in AD clinical trials, consists of memory, language, orientation, and praxis assessments. Its scores range from 0 to 70, with higher values indicating higher degree of deficit.

The Chinese version of Mini Mental State Examination (MMSE). It includes six factors: orientation, immediate recall, attention, short-term memory, and language, with a maximum score of 30.

The Chinese version of Montreal Cognitive Assessment (MoCA). It includes attention and concentration, executive functions, memory, language, visuospatial abilities, abstract thinking, calculating abilities and orientation. The cutoff value of MoCA on Chinese population is ≥ 26 with education ≤ 12. The final score is the actual measured score plus one point.

The Chinese version of World Health Organization University of California-Los Angeles, Auditory Verbal Learning Test (WHO-UCLA AVLT): This test primarily for verbal memory, patients' short-term memory and the ability to learn new things, including immediate recall, delayed recall, long delayed recognition.

Statistical analysis {#s4_7}
--------------------

Demographics were analyzed using the Mann-Whitney U test for continuous variables and Fisher\'s exact test for categorical variables. All of the assessments were analyzed *via* repeated-measures analysis of covariance, including age, gender, and duration of education as covariates to evaluate the consecutive changes in each score from baseline to after rTMS treatment between the treatment and sham groups. The scores obtained immediately and 6 weeks after the end of rTMS-COG treatment were compared with those obtained at baseline by multiple comparisons with Bonferroni correction. All of these statistics were applied identically in the subgroup analysis. All analyses were performed using SPSS software (version 19.0, SPSS Inc., Chicago, IL, USA). Two-sided probability values of *p* \< 0.05 were considered statistically significant.
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